MedTrace Logo

Effectiveness of Niclosamide as Add-on Therapy to the Standard of Care Measures in COVID-19 Management

NCT04753619 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2021-06-22

No results posted yet for this study

Summary

Assessment of the Effectiveness of Niclosamide as Add on Therapy to the Standard of care Measures in COVID-19 Management in a randomized controlled clinical trial

Conditions

Interventions

DRUG

Niclosamide Oral Tablet

* NCS 2 grams orally loading dose chewable then 1g every 8 hours in the first day, then on the 2nd day 1g x3 for 7 days. \[ this means only in the first day 4 gm/d then on the second day 3g/d in 3 divided doses for 7 days\] * If the participant requires mechanical ventilation over the course of the study, NGT may be administered via nasogastric (NG) or orogastric (OG) tube and, if possible, should be administered with a scheduled nasogastric (NG) or orogastric (OG) feeding.

Sponsors & Collaborators

  • University of Baghdad

    lead OTHER

Principal Investigators

  • Ahmed S Abdulamir, Professor · College of Medicine-Al-Nahrain University

  • Faiq I. Gorial, Prof · College of Medicine-University of Baghdad

  • Manal K abdulrrazaq, Professor · College of Medicine-University of Baghdad

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-03
Primary Completion
2021-12-03
Completion
2021-12-03

Countries

  • Iraq

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04753619 on ClinicalTrials.gov